Trial Profile
A Phase 1/2 single-arm study evaluating the safety and efficacy of eribulin mesilate in combination with irinotecan in children with refractory or recurrent solid tumors
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 30 Jun 2022
Price :
$35
*
At a glance
- Drugs Eribulin (Primary) ; Irinotecan (Primary)
- Indications Ewing's sarcoma; Hepatoblastoma; Neuroblastoma; Rhabdomyosarcoma; Soft tissue sarcoma; Solid tumours; Wilms' tumour
- Focus Adverse reactions; Therapeutic Use
- Sponsors Eisai Co Ltd
- 16 Dec 2021 The trial has been completed in Poland, Germany and Italy. Ongoing in Spain and no longer in UK according to European Clinical Trials Database record. Trial status is as per NCT
- 26 Jul 2021 Status changed from recruiting to completed.
- 31 May 2020 Results (data cut-off: July 14, 2019) presented at the 56th Annual Meeting of the American Society of Clinical Oncology